Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Behaviors and Mental Disorders

Rare Diseases

Lymphoma

Aggression

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Rituximab

Antineoplastic Agents, Immunological

Immunologic Factors

DHAP

autologous stem cell transplantation

Michael Koenigsmann, PD Dr. med

Michael Koenigsmann, PD Dr. med.

This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or refractory aggressive Non- Hodgkins's Lymphoma.

Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and cisplatin followed by high dose chemotherapy with treosulfan, etoposide and cisplatin (TEC) an autologous peripheral blood stem cell transplantation(aPBSCT). In case of only partial remission a second identical high dose chemotherapy and aPBSCT follows. Patients with primary refractory disease or early relapse within 6 months should receive a allogenous stem cell transplantation. For Patients with CD 20 positive B-cell lymphoma the chemotherapy regiments DHAP and TEC are combined with rituximab.

Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma

University of Magdeburg

Symptoms and General Pathology

Digestive System Diseases

Recurrence

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Irinotecan

Antibodies

Antibodies, Monoclonal

Immune Checkpoint Inhibitors

Tislelizumab

Cetuximab

Immunoglobulins

tislelizumab combined with cetuximab and irinotecan

tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan

This is a single arm, open phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab + irinotecan in the treatment of Ras wild-type recurrent and refractory colorectal cancer. This study will include Ras wild-type colorectal cancer that failed at least second-line treatment in the past, including chemotherapy (oxaliplatin, irinotecan, fluorouracil) with or without targeted drugs (cetuximab, bevacizumab). 33 patients were planned to be treated with tislelizumab combined with cetuximab + irinotecan every 2 weeks. The enrollment time is expected to be 12 months and the follow-up is 24 months.

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

Phase II Clinical Study on the Efficacy and Safety of Immune Checkpoint Inhibitor Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory and Metastatic Colorectal Cancer

PD-L1 expression, tumor mutation burden (TMB) and proteins in blood samples

proportion of patients with complete and partial remission in the best efficacy

the best efficacy is the proportion of patients with complete remission, partial remission and stable disease

time from the start of medication to the initial progression of the disease

time from the start of medication to death

Shanghai Zhongshan Hospital

Director of Oncology Department

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma	NCT00384553	Non-Hodgkin's L...	Rituximab DHAP TEC autologous stem...	18 Years - 65 Years	University of Magdeburg
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC	NCT05143099	Colorectal Neop...	TEC	18 Years -	Shanghai Zhongshan Hospital
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC	NCT05143099	Colorectal Neop...	TEC	18 Years -	Shanghai Zhongshan Hospital

Spots Global Cancer Trial Database for tec

Every month we try and update this database with for tec cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for tec

Every month we try and update this database with for tec cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tec cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.